The raging COVID-19 pandemic has shaken our trust in science. This volume reviews the evolution of misconduct and fraud in science, the many steps taken to alleviate the problem, and the likelihood that it will continue, given our profit-driven healthcare system. Contents are set in a clinical context, wherein misconduct and fraud affect rational prescribing, a process that depends on balancing the risk–benefit ratio of treatments, whether pharmacologic or psychotherapeutic. The clinical consequences can be significant, in that the efficacy of treatments can be vastly overplayed, adverse effects minimized, and costs to the healthcare system increased if corrective measures are not taken.

Key Features